Intervertebral Disc Disease
9
0
0
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
11.1%
1 terminated out of 9 trials
88.9%
+2.4% vs benchmark
22%
2 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (9)
Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)
PASS OCT® Post-market Clinical Follow-up
A Study of SI-6603 in Patients With Lumbar Disc Herniation
A Study of SI-6603 in Patients With Lumbar Disc Herniation
Clinical and Radiological Evaluation of Patients With DDD Following TLIF With 3-D Printed Titanium Cage
A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®
A Prospective Study of NuCel® in Cervical Spine Fusion
Efficacy Study of NuCel® in Patients Undergoing Fusion of the Lumbar Spine
Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease